{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T10:29:25Z","timestamp":1794479365034,"version":"4.9.1"},"reference-count":121,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,2]],"date-time":"2026-05-02T00:00:00Z","timestamp":1777680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000024","name":"Canadian Institutes of Health Research","doi-asserted-by":"publisher","award":["FDN-148413"],"award-info":[{"award-number":["FDN-148413"]}],"id":[{"id":"10.13039\/501100000024","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000156","name":"Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000156","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000038","name":"Natural Sciences and Engineering Research Council of Canada","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000038","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["OZR3939"],"award-info":[{"award-number":["OZR3939"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["SRP50 SRP95"],"award-info":[{"award-number":["SRP50 SRP95"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004418","name":"Vrije Universiteit Brussel","doi-asserted-by":"publisher","award":["OZR3584"],"award-info":[{"award-number":["OZR3584"]}],"id":[{"id":"10.13039\/501100004418","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003130","name":"Fonds Wetenschappelijk Onderzoek","doi-asserted-by":"publisher","award":["1SB0422N"],"award-info":[{"award-number":["1SB0422N"]}],"id":[{"id":"10.13039\/501100003130","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.biopha.2026.119488","type":"journal-article","created":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T22:46:47Z","timestamp":1778539607000},"page":"119488","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Dual-target opioid\/neurotensin ligands drive potent and safer analgesia in vivo"],"prefix":"10.1016","volume":"199","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1937-450X","authenticated-orcid":false,"given":"\u00c9mile","family":"Breault","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jolien De","family":"Neve","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amirmohammad","family":"Ranjbaran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-8583-0738","authenticated-orcid":false,"given":"Alexandre","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ines","family":"Robberechts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9rique","family":"Lussier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F\u00e9lix","family":"B\u00e9lair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian J.","family":"Holleran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Brochu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5850-8219","authenticated-orcid":false,"given":"Nicol\u00f2","family":"Bisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9077-6600","authenticated-orcid":false,"given":"J\u00e9r\u00f4me","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Longpr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Gendron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Ballet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7627-701X","authenticated-orcid":false,"given":"Philippe","family":"Sarret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.biopha.2026.119488_bib1","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2015-010364","article-title":"Prevalence of chronic pain in the UK: a systematic review and meta-analysis of population studies","volume":"6","author":"Fayaz","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.biopha.2026.119488_bib2","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.ejpain.2005.06.009","article-title":"Survey of chronic pain in Europe: prevalence, impact on daily life, and treatment","volume":"10","author":"Breivik","year":"2006","journal-title":"Eur. J. Pain. Lond. Engl."},{"key":"10.1016\/j.biopha.2026.119488_bib3","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1016\/S0140-6736(21)00393-7","article-title":"Chronic pain: an update on burden, best practices, and new advances","volume":"397","author":"Cohen","year":"2021","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2026.119488_bib4","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.36076\/ppj.2008\/11\/S105","article-title":"R. Vallejo, Opioid complications and side effects","volume":"11","author":"Benyamin","year":"2008","journal-title":"Pain. Physician"},{"key":"10.1016\/j.biopha.2026.119488_bib5","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41380-020-0661-4","article-title":"The changing opioid crisis: development, challenges and opportunities","volume":"26","author":"Volkow","year":"2021","journal-title":"Mol. Psychiatry"},{"key":"10.1016\/j.biopha.2026.119488_bib6","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.abb.2018.10.011","article-title":"Recent progress in non-opioid analgesic peptides","volume":"660","author":"P\u00e9rez de Vega","year":"2018","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.biopha.2026.119488_bib7","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s12964-020-00569-y","article-title":"The role of Neurotensin and its receptors in non-gastrointestinal cancers: a review","volume":"18","author":"Nikolaou","year":"2020","journal-title":"Cell Commun. Signal. CCS"},{"key":"10.1016\/j.biopha.2026.119488_bib8","series-title":"in: Ref. Module Neurosci. Biobehav. Psychol","article-title":"Neurotensin and Its Receptors\u2606","author":"Sarret","year":"2017"},{"key":"10.1016\/j.biopha.2026.119488_bib9","doi-asserted-by":"crossref","first-page":"840","DOI":"10.2174\/1381612820666141027124915","article-title":"The roles of neurotensin and its analogues in pain","volume":"21","author":"Feng","year":"2015","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.biopha.2026.119488_bib10","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fchem.2020.00406","article-title":"Insightful backbone modifications preventing proteolytic degradation of neurotensin analogs improve nts1-induced protective hypothermia","volume":"8","author":"Previti","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib11","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ejphar.2015.05.025","article-title":"Emerging role of neurotensin in regulation of the cardiovascular system","volume":"762","author":"Osadchii","year":"2015","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib12","article-title":"Opening the amino acid toolbox for peptide-based NTS2-selective ligands as promising lead compounds for pain management","volume":"29","author":"Previti","year":"2023","journal-title":"J. Pept. Sci. Off. Publ. Eur. Pept. Soc."},{"key":"10.1016\/j.biopha.2026.119488_bib13","first-page":"3741","article-title":"Spinal NTS2 receptor activation reverses signs of neuropathic pain","volume":"27","author":"T\u00e9treault","year":"2013","journal-title":"FASEB J. Off. Publ. Fed. Am. Soc. Exp. Biol."},{"key":"10.1016\/j.biopha.2026.119488_bib14","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.brainres.2009.07.086","article-title":"NT69L, a novel analgesic, shows synergy with morphine","volume":"1294","author":"Boules","year":"2009","journal-title":"Brain Res"},{"key":"10.1016\/j.biopha.2026.119488_bib15","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejphar.2019.01.048","article-title":"The combination of opioid and neurotensin receptor agonists improves their analgesic\/adverse effect ratio","volume":"848","author":"Eiselt","year":"2019","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/128_2010_76","article-title":"Twin and triplet drugs in opioid research","volume":"299","author":"Fujii","year":"2011","journal-title":"Top. Curr. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2024.107408","article-title":"Multitarget ligands that comprise opioid\/nonopioid pharmacophores for pain management: current state of the science","volume":"209","author":"Breault","year":"2024","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.biopha.2026.119488_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2020.108232","article-title":"Novel hybrid compounds, opioid agonist+melanocortin 4 receptor antagonist, as efficient analgesics in mouse chronic constriction injury model of neuropathic pain","volume":"178","author":"Starnowska-Sok\u00f3\u0142","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2026.119488_bib19","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/j.peptides.2008.03.022","article-title":"Structure\u2013activity relationships of bifunctional cyclic disulfide peptides based on overlapping pharmacophores at opioid and cholecystokinin receptors","volume":"29","author":"Agnes","year":"2008","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2026.119488_bib20","doi-asserted-by":"crossref","first-page":"3078","DOI":"10.1021\/acschemneuro.2c00442","article-title":"OFP011 cyclic peptide as a multifunctional agonist for opioid\/neuropeptide ff receptors with improved blood-brain barrier penetration","volume":"13","author":"Zhang","year":"2022","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2026.119488_bib21","doi-asserted-by":"crossref","first-page":"7603","DOI":"10.1021\/acs.jmedchem.4c00442","article-title":"Multitarget \u03bc-opioid receptor agonists\u2500neuropeptide ff receptor antagonists induce potent antinociception with reduced adverse side effects","volume":"67","author":"De Neve","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib22","doi-asserted-by":"crossref","first-page":"6335","DOI":"10.1016\/j.bmc.2012.09.003","article-title":"Synthesis, biological activity and structure-activity relationship of endomorphin-1\/substance P derivatives","volume":"20","author":"Varamini","year":"2012","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib23","doi-asserted-by":"crossref","first-page":"3716","DOI":"10.1016\/j.bmcl.2015.06.030","article-title":"Discovery of tripeptide-derived multifunctional ligands possessing delta\/mu opioid receptor agonist and neurokinin 1 receptor antagonist activities","volume":"25","author":"Nair","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119488_bib24","first-page":"5406","article-title":"Harnessing the Anti-Nociceptive Potential of NK2 and NK3 Ligands in the Design of New Multifunctional \u03bc\/\u03b4-Opioid Agonist-Neurokinin Antagonist Peptidomimetics","volume":"26","author":"Gadais","year":"2021","journal-title":"Mol. Basel Switz."},{"key":"10.1016\/j.biopha.2026.119488_bib25","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/jm4005219","article-title":"Bivalent ligands that target \u03bc opioid (MOP) and cannabinoid1 (CB1) receptors are potent analgesics devoid of tolerance","volume":"56","author":"Le Naour","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib26","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S0968-0896(01)00356-X","article-title":"Guanidinium and aminoimidazolinium derivatives of N-(4-piperidyl)propanamides as potential ligands for \u03bc opioid and I2-imidazoline receptors: synthesis and pharmacological screening","volume":"10","author":"Montero","year":"2002","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib27","doi-asserted-by":"crossref","first-page":"4148","DOI":"10.1016\/j.bmcl.2015.08.014","article-title":"Design, synthesis and biological evaluation of multifunctional ligands targeting opioid and bradykinin 2 receptors","volume":"25","author":"Deekonda","year":"2015","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2026.119488_bib28","doi-asserted-by":"crossref","first-page":"11595","DOI":"10.1073\/pnas.1305461110","article-title":"Ligands that interact with putative MOR-mGluR5 heteromer in mice with inflammatory pain produce potent antinociception","volume":"110","author":"Akg\u00fcn","year":"2013","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2026.119488_bib29","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/cbdd.12479","article-title":"Design, synthesis and biological evaluation of two opioid agonist and cav 2.2 blocker multitarget ligands","volume":"86","author":"Mollica","year":"2015","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.biopha.2026.119488_bib30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1097\/FBP.0b013e3283474a3a","article-title":"Analgesic synergy of neurotensin receptor subtype 2 agonist NT79 and morphine","volume":"22","author":"Boules","year":"2011","journal-title":"Behav. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib31","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/1744-8069-6-86","article-title":"PK20, a new opioid-neurotensin hybrid peptide that exhibits central and peripheral antinociceptive effects","volume":"6","author":"Kleczkowska","year":"2010","journal-title":"Mol. Pain."},{"key":"10.1016\/j.biopha.2026.119488_bib32","doi-asserted-by":"crossref","first-page":"12929","DOI":"10.1021\/acs.jmedchem.0c01376","article-title":"Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure\u2013Activity Relationship Studies","volume":"63","author":"Gonzalez","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib33","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/164_2017_32","article-title":"The Delta Opioid Receptor in Pain Control","volume":"247","author":"Abdallah","year":"2018","journal-title":"Handb. Exp. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib34","doi-asserted-by":"crossref","first-page":"4535","DOI":"10.1021\/acschemneuro.9b00390","article-title":"Neurotensin Analogues Containing Cyclic Surrogates of Tyrosine at Position 11 Improve NTS2 Selectivity Leading to Analgesia without Hypotension and Hypothermia","volume":"10","author":"Eiselt","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2026.119488_bib35","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40263-025-01172-w","article-title":"Opioid Analgesics: Rise and Fall of Ligand Biased Signaling and Future Perspectives in the Quest for the Holy Grail","volume":"39","author":"Breault","year":"2025","journal-title":"CNS Drugs"},{"key":"10.1016\/j.biopha.2026.119488_bib36","doi-asserted-by":"crossref","DOI":"10.1126\/scisignal.aaz3140","article-title":"Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists","volume":"13","author":"Gillis","year":"2020","journal-title":"Sci. Signal"},{"key":"10.1016\/j.biopha.2026.119488_bib37","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/mol.119.119214","article-title":"Intrinsic Efficacy of Opioid Ligands and Its Importance for Apparent Bias, Operational Analysis, and Therapeutic Window","volume":"98","author":"Gillis","year":"2020","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib38","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1146\/annurev-pharmtox-052120-091058","article-title":"Biased Agonism: Lessons from Studies of Opioid Receptor Agonists","volume":"63","author":"Kelly","year":"2023","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.biopha.2026.119488_bib39","doi-asserted-by":"crossref","DOI":"10.1021\/acsptsci.4c00236","article-title":"Design, Synthesis, and in vitro characterization of proteolytically-stable opioid-neurotensin hybrid peptidomimetics","author":"De Neve","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"10.1016\/j.biopha.2026.119488_bib40","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","article-title":"Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction","volume":"22","author":"Cheng","year":"1973","journal-title":"Biochem. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib41","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1021\/acschemneuro.6b00097","article-title":"Identification of 2-({[1-(4-Fluorophenyl)-5-(2-methoxyphenyl)-1 H -pyrazol-3-yl]carbonyl}amino)tricyclo[3.3.1.13,7]decane-2-carboxylic Acid (NTRC-844) as a Selective Antagonist for the Rat Neurotensin Receptor Type 2","volume":"7","author":"Thomas","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.biopha.2026.119488_bib42","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0031-9384(95)00046-L","article-title":"J.W. Grau, Tail-flick test. I: Impact of a suprathreshold exposure to radiant heat on pain reactivity in rats","volume":"58","author":"Kallina","year":"1995","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2026.119488_bib43","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/0304-3959(92)90003-T","article-title":"The formalin test: an evaluation of the method","volume":"51","author":"Tj\u00f8lsen","year":"1992","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib44","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/0304-3959(93)90098-A","article-title":"The formalin test: a validation of the weighted-scores method of behavioural pain rating","volume":"54","author":"Coderre","year":"1993","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib45","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0304-3959(77)90130-0","article-title":"The formalin test: a quantitative study of the analgesic effects of morphine, meperidine, and brain stem stimulation in rats and cats","volume":"4","author":"Dubuisson","year":"1977","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1093\/ilar.40.3.129","article-title":"Postoperative Models of Nociception","volume":"40","author":"Brennan","year":"1999","journal-title":"ILAR J."},{"key":"10.1016\/j.biopha.2026.119488_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atc.2004.11.009","article-title":"Mechanisms of incisional pain","volume":"23","author":"Brennan","year":"2005","journal-title":"Anesthesiol. Clin. N. Am."},{"key":"10.1016\/j.biopha.2026.119488_bib48","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12974-021-02125-y","article-title":"Mechanistic insights into the role of the chemokine CCL2\/CCR2 axis in dorsal root ganglia to peripheral inflammation and pain hypersensitivity","volume":"18","author":"Dansereau","year":"2021","journal-title":"J. Neuroinflamm."},{"key":"10.1016\/j.biopha.2026.119488_bib49","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.physbeh.2011.05.015","article-title":"Weight bearing evaluation in inflammatory, neuropathic and cancer chronic pain in freely moving rats","volume":"104","author":"T\u00e9treault","year":"2011","journal-title":"Physiol. Behav."},{"key":"10.1016\/j.biopha.2026.119488_bib50","doi-asserted-by":"crossref","DOI":"10.14814\/phy2.14975","article-title":"The neuronal potassium current IA is a potential target for pain during chronic inflammation","volume":"9","author":"Biet","year":"2021","journal-title":"Physiol. Rep."},{"key":"10.1016\/j.biopha.2026.119488_bib51","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0165-0270(94)90144-9","article-title":"Quantitative assessment of tactile allodynia in the rat paw","volume":"53","author":"Chaplan","year":"1994","journal-title":"J. Neurosci. Methods"},{"key":"10.1016\/j.biopha.2026.119488_bib52","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0013774","article-title":"Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain","volume":"5","author":"Dor\u00e9-Savard","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.biopha.2026.119488_bib53","first-page":"H484","article-title":"An in situ brain perfusion technique to study cerebrovascular transport in the rat","volume":"247","author":"Takasato","year":"1984","journal-title":"Am. J. Physiol."},{"key":"10.1016\/j.biopha.2026.119488_bib54","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1172\/JCI70647","article-title":"Conjugation of a brain-penetrant peptide with neurotensin provides antinociceptive properties","volume":"124","author":"Demeule","year":"2014","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119488_bib55","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1111\/j.1471-4159.1990.tb04886.x","article-title":"Capillary depletion method for quantification of blood-brain barrier transport of circulating peptides and plasma proteins","volume":"54","author":"Triguero","year":"1990","journal-title":"J. Neurochem."},{"key":"10.1016\/j.biopha.2026.119488_bib56","first-page":"221","article-title":"Bifunctional opioid\/nociceptin hybrid KGNOP1 effectively attenuates pain-related behaviour in a rat model of neuropathy","volume":"104","author":"Starnowska","year":"2017","journal-title":"Eur. J. Pharm. Sci. Off. J. Eur. Fed. Pharm. Sci."},{"key":"10.1016\/j.biopha.2026.119488_bib57","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/0014-2999(94)90543-6","article-title":"Morphine-induced straub tail response: mediated by central mu2-opioid receptor","volume":"263","author":"Nath","year":"1994","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib58","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0304-3959(90)90073-M","article-title":"The rat paw formalin test: comparison of noxious agents","volume":"40","author":"Wheeler-Aceto","year":"1990","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib59","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/1744-8069-5-38","article-title":"Evidence for a role of NTS2 receptors in the modulation of tonic pain sensitivity","volume":"5","author":"Roussy","year":"2009","journal-title":"Mol. Pain."},{"key":"10.1016\/j.biopha.2026.119488_bib60","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbr.2021.113189","article-title":"Metabolically stable neurotensin analogs exert potent and long-acting analgesia without hypothermia","volume":"405","author":"Vivancos","year":"2021","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.biopha.2026.119488_bib61","article-title":"Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog, Biomed. Pharmacother","volume":"141","author":"Chartier","year":"2021","journal-title":"Biomedecine Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib62","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acs.jmedchem.0c01726","article-title":"Design, Structural optimization, and characterization of the first selective macrocyclic neurotensin receptor type 2 non-opioid analgesic","volume":"64","author":"Chartier","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.ejphar.2009.01.004","article-title":"Pharmacological assessment of the rat formalin test utilizing the clinically used analgesic drugs gabapentin, lamotrigine, morphine, duloxetine, tramadol and ibuprofen: influence of low and high formalin concentrations","volume":"605","author":"Munro","year":"2009","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib64","doi-asserted-by":"crossref","first-page":"3760","DOI":"10.1172\/JCI42843","article-title":"Nociceptors: the sensors of the pain pathway","volume":"120","author":"Dubin","year":"2010","journal-title":"J. Clin. Invest"},{"key":"10.1016\/j.biopha.2026.119488_bib65","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3389\/fnmol.2017.00284","article-title":"Methods Used to Evaluate Pain Behaviors in Rodents","volume":"10","author":"Deuis","year":"2017","journal-title":"Front. Mol. Neurosci."},{"key":"10.1016\/j.biopha.2026.119488_bib66","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/0304-3959(87)90023-6","article-title":"Subcutaneous formalin-induced activity of dorsal horn neurones in the rat: differential response to an intrathecal opiate administered pre or post formalin","volume":"30","author":"Dickenson","year":"1987","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib67","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0304-3959(98)00194-8","article-title":"Differential effects of neurotoxic destruction of descending noradrenergic pathways on acute and persistent nociceptive processing","volume":"80","author":"Martin","year":"1999","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib68","doi-asserted-by":"crossref","first-page":"7739","DOI":"10.1073\/pnas.96.14.7739","article-title":"Distinct neurochemical features of acute and persistent pain","volume":"96","author":"Basbaum","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.biopha.2026.119488_bib69","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2024.176775","article-title":"BNT12, a novel hybrid peptide of opioid and neurotensin pharmacophores, produces potent central antinociception with limited side effects","volume":"978","author":"Wang","year":"2024","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib70","doi-asserted-by":"crossref","DOI":"10.1002\/anie.202405941","article-title":"Development of Macrocyclic Neurotensin Receptor Type\u20092 (NTS2) Opioid-Free Analgesics","volume":"63","author":"Desgagn\u00e9","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"10.1016\/j.biopha.2026.119488_bib71","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1021\/acs.jmedchem.0c01726","article-title":"Design, Structural Optimization, and Characterization of the First Sel ective Macrocyclic Neurotensin Receptor Type 2 Non-opioid Analgesic","volume":"64","author":"Chartier","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib72","article-title":"Pharmacodynamic and pharmacokinetic profiles of a neurotensin receptor type 2 (NTS2) analgesic macrocyclic analog, Biomed. Pharmacother","volume":"141","author":"Chartier","year":"2021","journal-title":"Biomedecine Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib73","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/j.neuroscience.2007.09.060","article-title":"Essential role of mu opioid receptor in the regulation of delta opioid receptor-mediated antihyperalgesia","volume":"150","author":"Gendron","year":"2007","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2026.119488_bib74","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.neuroscience.2011.03.052","article-title":"Spinal activation of delta opioid receptors alleviates cancer-related bone pain","volume":"183","author":"Otis","year":"2011","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2026.119488_bib75","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0304-3959(98)00081-5","article-title":"Morphine, the NMDA receptor antagonist MK801 and the tachykinin NK1 receptor antagonist RP67580 attenuate the development of inflammation-induced progressive tactile hypersensitivity","volume":"77","author":"Ma","year":"1998","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib76","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2020.593647","article-title":"Morphine Antinociception Restored by Use of Methadone in the Morphine-Resistant Inflammatory Pain State","volume":"11","author":"Watanabe","year":"2020","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib77","article-title":"Neurotensin-expressing lateral hypothalamic neurons alleviate neuropat hic and inflammatory pain via neurotensin receptor signaling","volume":"16","author":"Khan","year":"2024","journal-title":"Neurobiol. Pain."},{"key":"10.1016\/j.biopha.2026.119488_bib78","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1016\/S0140-6736(06)68700-X","article-title":"Persistent postsurgical pain: risk factors and prevention","volume":"367","author":"Kehlet","year":"2006","journal-title":"Lancet Lond. Engl."},{"key":"10.1016\/j.biopha.2026.119488_bib79","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1097\/ACO.0000000000001426","article-title":"Mitigating and preventing perioperative opioid-related harm","volume":"37","author":"Harbell","year":"2024","journal-title":"Curr. Opin. Anaesthesiol."},{"key":"10.1016\/j.biopha.2026.119488_bib80","doi-asserted-by":"crossref","first-page":"S33","DOI":"10.1016\/j.pain.2010.11.005","article-title":"Pathophysiology of postoperative pain","volume":"152","author":"Brennan","year":"2011","journal-title":"Pain"},{"key":"10.1016\/j.biopha.2026.119488_bib81","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41386-022-01416-z","article-title":"Opioid antagonism in humans: a primer on optimal dose and timing for central mu-opioid receptor blockade","volume":"48","author":"Tr\u00f8stheim","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.biopha.2026.119488_bib82","doi-asserted-by":"crossref","first-page":"123","DOI":"10.3389\/fphar.2013.00123","article-title":"Targeting pain and inflammation by peripherally acting opioids","volume":"4","author":"Stein","year":"2013","journal-title":"Front. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib83","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1124\/jpet.104.075176","article-title":"Peripheral versus central antinociceptive actions of 6-amino acid-substituted derivatives of 14-O-methyloxymorphone in acute and inflammatory pain in the rat","volume":"312","author":"F\u00fcrst","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119488_bib84","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.ejphar.2013.04.043","article-title":"Peripheral antinociceptive efficacy and potency of a novel opioid compound 14-O-MeM6SU in comparison to known peptide and non-peptide opioid agonists in a rat model of inflammatory pain","volume":"713","author":"Khalefa","year":"2013","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib85","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1021\/acs.jmedchem.5b01976","article-title":"Bifunctional Peptide-Based Opioid Agonist-Nociceptin Antagonist Ligands for Dual Treatment of Acute and Neuropathic Pain","volume":"59","author":"Guillemyn","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib86","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S0022-3565(25)20113-6","article-title":"Poor permeability of morphine 3-glucuronide and morphine 6-glucuronide through the blood-brain barrier in the rat","volume":"278","author":"Bickel","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119488_bib87","doi-asserted-by":"crossref","first-page":"9549","DOI":"10.1021\/jm3008079","article-title":"Variation of the net charge, lipophilicity, and side chain flexibility in Dmt(1)-DALDA: Effect on Opioid Activity and Biodistribution","volume":"55","author":"Novoa","year":"2012","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib88","series-title":"Blood-Spinal Cord Brain Barriers Health Dis","first-page":"299","article-title":"16 - Blood-Central Nervous System Barriers in Morphine Dependence and Withdrawal","author":"Sharma","year":"2004"},{"key":"10.1016\/j.biopha.2026.119488_bib89","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.peptides.2010.03.029","article-title":"Analytical characterization and comparison of the blood-brain barrier permeability of eight opioid peptides","volume":"31","author":"Van Dorpe","year":"2010","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2026.119488_bib90","first-page":"2","article-title":"Bioavailability of endomorphins and the blood-brain barrier--a review","volume":"10","author":"Perlikowska","year":"2014","journal-title":"Med. Chem. Shariqah U. Arab Emir."},{"key":"10.1016\/j.biopha.2026.119488_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.neuropharm.2025.110324","article-title":"Novel chimeric peptides of endomorphin-2 and the active fragments of ghrelin exhibit blood-brain barrier permeability and central antinociceptive effects with reduced opioid-related side effects","volume":"269","author":"Liu","year":"2025","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2026.119488_bib92","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1111\/j.1749-6632.1982.tb31575.x","article-title":"Neurotensin and thermoregulation","volume":"400","author":"Bissette","year":"1982","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.biopha.2026.119488_bib93","doi-asserted-by":"crossref","first-page":"406","DOI":"10.3389\/fchem.2020.00406","article-title":"Insightful Backbone Modifications Preventing Proteolytic Degradation o f Neurotensin Analogs Improve NTS1-Induced Protective Hypothermia","volume":"8","author":"Previti","year":"2020","journal-title":"Front. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib94","doi-asserted-by":"crossref","first-page":"7103","DOI":"10.1021\/acs.jmedchem.8b00175","article-title":"Structural Optimization and Characterization of Potent Analgesic Macrocyclic Analogues of Neurotensin (8-13)","volume":"61","author":"Sousbie","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2026.119488_bib95","doi-asserted-by":"crossref","first-page":"36","DOI":"10.3389\/fendo.2013.00036","article-title":"Diverse Roles of Neurotensin Agonists in the Central Nervous System","volume":"4","author":"Boules","year":"2013","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2026.119488_bib96","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pbb.2004.12.005","article-title":"Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys","volume":"80","author":"Fantegrossi","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.biopha.2026.119488_bib97","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/0014-2999(81)90469-6","article-title":"The hypotensive effect of centrally administered neurotensin in rats","volume":"69","author":"Rioux","year":"1981","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib98","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0006-8993(02)03271-7","article-title":"Targeted inactivation of the neurotensin type 1 receptor reveals its role in body temperature control and feeding behavior but not in analgesia","volume":"953","author":"Remaury","year":"2002","journal-title":"Brain Res"},{"key":"10.1016\/j.biopha.2026.119488_bib99","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1124\/jpet.300.1.305","article-title":"The effects of deleting the mouse neurotensin receptor NTR1 on central and peripheral responses to neurotensin","volume":"300","author":"Pettibone","year":"2002","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119488_bib100","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.euroneuro.2009.01.004","article-title":"Involvement of the neurotensin receptor 1 in the behavioral effects of two neurotensin agonists, NT-2 and NT69L: lack of hypothermic, antinociceptive and antipsychotic actions in receptor knockout mice","volume":"19","author":"Mechanic","year":"2009","journal-title":"Eur. Neuropsychopharmacol. J. Eur. Coll. Neuropsychopharmacol."},{"key":"10.1016\/j.biopha.2026.119488_bib101","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.1016\/0024-3205(83)90421-6","article-title":"Release of histamine and adrenaline in vivo following intravenous administration of neurotensin","volume":"32","author":"Oishi","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.biopha.2026.119488_bib102","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0196-9781(80)90011-X","article-title":"Hypothermia elicited by the intracerebral microinjection of neurotensi","volume":"1","author":"Martin","year":"1980","journal-title":"N. Pept."},{"key":"10.1016\/j.biopha.2026.119488_bib103","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.pbb.2004.12.005","article-title":"Antinociceptive, hypothermic, hypotensive, and reinforcing effects of a novel neurotensin receptor agonist, NT69L, in rhesus monkeys","volume":"80","author":"Fantegrossi","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.biopha.2026.119488_bib104","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0006-8993(85)90031-9","article-title":"Microinjection of neurotensin into the ventral tegmental area produces hypothermia: evaluation of dopaminergic mediation","volume":"326","author":"Kalivas","year":"1985","journal-title":"Brain Res"},{"key":"10.1016\/j.biopha.2026.119488_bib105","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/0196-9781(80)90011-X","article-title":"Hypothermia elicited by the intracerebral microinjection of neurotensin","volume":"1","author":"Martin","year":"1980","journal-title":"Peptides"},{"key":"10.1016\/j.biopha.2026.119488_bib106","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1111\/j.1553-2712.2001.tb01126.x","article-title":"Neurotensin analog NT69L induces rapid and prolonged hypothermia after hypoxic ischemia, Acad. Emerg. Med. Off. J. Soc","volume":"8","author":"Katz","year":"2001","journal-title":"Acad. Emerg. Med."},{"key":"10.1016\/j.biopha.2026.119488_bib107","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neuropharm.2009.07.001","article-title":"The acute and subchronic effects of a brain-penetrating, neurotensin-1 receptor agonist on feeding, body weight and temperature","volume":"58","author":"Feifel","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.biopha.2026.119488_bib108","doi-asserted-by":"crossref","DOI":"10.3389\/fnsyn.2021.620145","article-title":"N-oleoylglycine and n-oleoylalanine do not modify tolerance to nociception, hyperthermia, and suppression of activity produced by morphine","volume":"13","author":"Rock","year":"2021","journal-title":"Front. Synaptic Neurosci."},{"key":"10.1016\/j.biopha.2026.119488_bib109","first-page":"1347","article-title":"Management of common opioid-induced adverse effects","volume":"74","author":"Swegle","year":"2006","journal-title":"Am. Fam. Physician"},{"key":"10.1016\/j.biopha.2026.119488_bib110","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/0163-7258(95)02053-5","article-title":"Insights into opioid action in the intestinal tract","volume":"69","author":"De Luca","year":"1996","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.biopha.2026.119488_bib111","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1124\/jpet.111.186320","article-title":"The role of \u03b2-arrestin2 in the mechanism of morphine tolerance in the mouse and guinea pig gastrointestinal tract","volume":"340","author":"Kang","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119488_bib112","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1124\/jpet.105.087254","article-title":"Morphine side effects in beta-arrestin 2 knockout mice","volume":"314","author":"Raehal","year":"2005","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.biopha.2026.119488_bib113","doi-asserted-by":"crossref","first-page":"2923","DOI":"10.1111\/bph.15004","article-title":"Morphine-induced respiratory depression is independent of \u03b2-arrestin2 signalling","volume":"177","author":"Kliewer","year":"2020","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib114","first-page":"1662","article-title":"The effects of neurotensin in the colon of patients with slow transit constipation","volume":"54","author":"Tomita","year":"2007","journal-title":"Hepatogastroenterology"},{"key":"10.1016\/j.biopha.2026.119488_bib115","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/S0140-6736(83)92028-7","article-title":"W.S. Peart, Neurotensin stimulates defaecation","volume":"321","author":"Calam","year":"1983","journal-title":"Lancet"},{"key":"10.1016\/j.biopha.2026.119488_bib116","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1111\/j.1476-5381.1996.tb15216.x","article-title":"Antagonism by SR 48692 of mechanical responses to neurotensin in rat intestine","volume":"117","author":"Mul\u00e8","year":"1996","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib117","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1056\/NEJMra1800222","article-title":"Opioid tolerance in critical illness","volume":"380","author":"Martyn","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.biopha.2026.119488_bib118","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.bjp.0707277","article-title":"Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of \u03bc- and \u03b4-opioid receptor antagonists","volume":"151","author":"Abul-Husn","year":"2007","journal-title":"Br. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173174","article-title":"Pain relief devoid of opioid side effects following central action of a silylated neurotensin analog","volume":"882","author":"T\u00e9treault","year":"2020","journal-title":"Eur. J. Pharm."},{"key":"10.1016\/j.biopha.2026.119488_bib120","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.suc.2021.09.003","article-title":"Multimodal analgesia in the era of the opioid epidemic","volume":"102","author":"Nicholas","year":"2022","journal-title":"Surg. Clin. North Am."},{"key":"10.1016\/j.biopha.2026.119488_bib121","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.anclin.2022.04.002","article-title":"Multimodal analgesia","volume":"40","author":"O\u2019Neill","year":"2022","journal-title":"Anesthesiol. Clin."}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600524X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S075333222600524X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,12]],"date-time":"2026-11-12T09:44:44Z","timestamp":1794476684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S075333222600524X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":121,"alternative-id":["S075333222600524X"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119488","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual-target opioid\/neurotensin ligands drive potent and safer analgesia in vivo","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2026.119488","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"119488"}}